Nuclear imaging for cardiac amyloidosis.

Area of Science:

• Cardiovascular Imaging
• Nuclear Medicine
• Diagnostic Radiology

Background:

• Cardiac amyloidosis diagnosis relies on endomyocardial biopsy, a gold standard with limitations.
• Non-invasive imaging modalities like echocardiography, MRI, and ultrasound lack specificity for cardiac amyloidosis.
• Nuclear medicine has emerged as a crucial tool for diagnosing and prognostically stratifying cardiac amyloidosis.

Purpose of the Study:

• To review current and future perspectives in nuclear medicine imaging for cardiac amyloidosis.
• To discuss the role of various radiopharmaceuticals in detecting amyloid deposits.
• To highlight the clinical applications of conventional nuclear medicine and positron emission tomography.

Main Methods:

• Review of established and emerging nuclear medicine techniques for cardiac amyloidosis.
• Analysis of radiopharmaceutical binding characteristics to amyloid infiltrates.
• Focus on bone scintigraphy, cardiac sympathetic innervation imaging, and positron emission tomography (PET).

Main Results:

• Nuclear medicine modalities provide precise diagnostic and prognostic information for cardiac amyloidosis.
• Radiopharmaceuticals exhibit differential binding based on amyloid type and affected organs.
• Conventional nuclear medicine and PET are key imaging tools.

Conclusions:

• Nuclear medicine plays a vital role in the non-invasive diagnosis and management of cardiac amyloidosis.
• Understanding radiopharmaceutical behavior is crucial for accurate interpretation.
• Future advancements promise enhanced diagnostic capabilities for cardiac amyloidosis.